Chiesi Wins FDA Approval for First Drug to Treat Ultra-Rare Enzyme Deficiency
Chiesi drug Lamzede is an engineered version of an enzyme that’s lacking in patients with the rare disease alpha-mannosidosis. FDA approval of the Chiesi drug comes about five years after European regulators authorized the product.